Our work spans over 20 years of scientific discoveries, including preclinical asthma models, translational research, and clinical trials. Our goal is to enhance the lives of individuals affected by chronic diseases.

Macrophage ImmunoTherapy is an innovative approach aimed at treating asthma patients through the use of autologous monocyte-derived macrophages. These macrophages have been genetically modified to eliminate PLA2G5, a key regulator of inflammation.

Our goal with cell therapy is to cure chronic diseases like asthma.